Synthesis and Development of Lantadene Congeners as Anticancer Agents

Abstract

The cancer is a rapid and uncontrolled growth of the cells, which metastasizes to the other parts of the body via the blood stream and the lymphatic system Numerous recent studies have revealed the close association between the cancer and inflammation The chimeric nonsteroidal anti inflammatory drugs NSAIDs are increasingly gaining the ground in recent years as the anticancer agents, since their target protein cyclooxygenase 2 COX 2 has been found to be actively involved in various malignancies Lantadenes are the pentacyclic triterpenoids present in the leaves of weed Lantana camara Linn These lantadenes, particularly lantadene A and B have been extensively explored in the last few years for their anticancer potential, predominantly by our group and have shown the remarkable cytotoxicity against the lung cancer cells, while suppressing the cell proliferation and differentiation regulating protein nuclear factor kappa B NF and#954;B Keeping these accounts in mind, we have synthesized the conjugates of NF and#954;B inhibitory scaffold lantadene and COX suppressing NSAIDs, as the novel dual acting inhibitors of NF and#954;B and COX, in the form of lantadene NSAID hybrid compounds Along with these lantadene NSAID conjugates, various other congeners of lantadenes were also synthesized newline